Medication governance under NZ ACC

Expert overview of medication management and regulatory requirements under New Zealand's Accident Compensation Corporation scheme

Published 3 April 2026

Introduction

New Zealand's unique no-fault accident compensation scheme, administered by the Accident Compensation Corporation (ACC), operates under the Accident Compensation Act 2001. Medication governance under the ACC scheme presents distinct considerations compared to fault-based insurance systems, as the scheme emphasizes recovery, rehabilitation, and prevention. For professional indemnity insurers and organizations managing ACC-related claims or health interventions, understanding medication governance requirements under the ACC framework is essential.

This article provides a specialist overview of medication governance principles and regulatory requirements applicable to ACC-covered conditions in New Zealand.

Legislative Framework and ACC Governance

The Accident Compensation Act 2001 (NZ) establishes the legislative foundation for the ACC scheme. The scheme provides no-fault compensation for accidental injuries, covering medical treatment and rehabilitation costs. Medications are considered part of the covered treatment where they are necessary for the treatment and rehabilitation of an ACC-covered injury.

The ACC operates under several key principles that influence medication governance:

• Principle of prevention: The ACC emphasizes prevention of injury and management approaches that reduce future injury risk.
• Rehabilitation focus: Treatment, including medications, should support rehabilitation and functional recovery objectives.
• Sustainability: Treatment approaches should be appropriate for long-term claimant outcomes, not just acute symptom management.
• Evidence-based practice: Treatments should be based on established clinical evidence and guidelines.
• Efficiency: Treatment should represent appropriate use of scheme resources while supporting claimant outcomes.

The ACC provides funding for treatment where it is necessary, reasonable, and appropriate for recovery. Medications fall within this framework, and ACC providers (including healthcare practitioners and pharmacists) are expected to provide evidence-based medication management consistent with these principles.

Prescribing Standards and Evidence-Based Practice in NZ

New Zealand prescribers follow the New Zealand Formulary, clinical practice guidelines published by relevant health professional colleges, and international evidence-based standards such as the Therapeutic Guidelines (Australian version, adapted for NZ context). For ACC-covered conditions, several medication-related considerations warrant specific attention.

Pain Management Approach

Pain management is frequently the central medication issue in ACC claims. Current best practice emphasizes multimodal pain management combining physical therapy, psychological interventions, and appropriately selected pharmacological therapy. The ACC strongly supports active rehabilitation approaches alongside pain management. For analgesic prescribing:

• Non-opioid analgesics (paracetamol, NSAIDs) should be prioritized where clinically appropriate.
• Opioid prescribing should be applied cautiously, with clear clinical justification and explicit deprescribing plans.
• Pain management should be integrated with rehabilitation and mobilization to support functional recovery.
• Long-term opioid therapy warrants regular review and assessment of continued necessity.

Muscle Relaxants and Spasticity

Muscle relaxants such as diazepam and benzodiazepines are sometimes prescribed for acute muscle spasm in ACC injuries. Current best practice recommends limiting benzodiazepine prescribing to short-term use (typically 2-4 weeks maximum) due to dependence risk and impact on rehabilitation. Physiotherapy and exercise-based interventions should be prioritized.

Psychotropic Medications and Psychological Support

ACC-covered injuries frequently result in mood disturbance, anxiety, or post-traumatic stress. Selective serotonin reuptake inhibitors (SSRIs) are considered first-line pharmacological treatment. Importantly, the ACC scheme also funds psychological interventions such as cognitive-behavioral therapy, and these should be provided alongside or instead of pharmacological therapy where appropriate.

Benzodiazepine Prescribing Governance

Benzodiazepines warrant particular attention in ACC medication governance due to dependence risk and potential impedance of rehabilitation. The ACC scheme has increasingly emphasized appropriate benzodiazepine prescribing, with focus on time-limited therapy. Best practice includes:

• Time-limited prescribing (2-4 weeks maximum) with explicit deprescribing plan documented from outset.
• Regular clinical review by the prescriber, particularly where prescribing extends beyond initial periods.
• Alternative interventions prioritized, including psychological support and sleep hygiene optimization.
• Documentation of dependence risk assessment, particularly for claimants with personal or family history of substance use.

The ACC scheme generally does not support prolonged benzodiazepine prescribing, as such use impairs rehabilitation and functional recovery. Providers should expect review of ongoing benzodiazepine therapy for ACC-covered claimants.

Medsafe Regulation and Medication Scheduling

New Zealand medications are regulated by Medsafe, the regulatory authority within the Ministry of Health. Medications are classified into several scheduling categories under the Misuse of Drugs Act 1975 and the Medicines Act 1981. Schedule 8 controlled drugs (equivalent to Australia's Schedule 8) include opioids and other controlled medications.

In ACC contexts, controlled medication prescribing should be:

• Time-limited with clear clinical justification documented.
• Subject to regular review by the prescriber, with assessment of continued necessity.
• Accompanied by risk screening for dependence, particularly for claimants with personal or family history of substance use disorder.
• Integrated with rehabilitation planning to support functional recovery.

Pharmacy Services and Medication Support

Community pharmacists in New Zealand play an important role in medication counseling, review, and support for ACC claimants. Pharmacy services relevant to ACC claims include:

Organizations managing ACC claims or supporting ACC claimants may benefit from engaging pharmacy services in scenarios including:

• Complex polypharmacy requiring rationalization or deprescribing.
• Long-term medication use requiring review and optimization.
• Benzodiazepine or opioid dependence risk requiring deprescribing support.
• Medication-related functional impairment affecting rehabilitation progress.

Return to Work and Medication Implications

Supported return to work is a key objective of the ACC scheme. Medication selection should be considered in relation to functional capacity and work feasibility. Medications impairing alertness, cognition, or motor function may impact return-to-work capability, particularly in safety-critical roles.

Healthcare practitioners should document:

• Functional impact of medications, including effects on alertness, cognition, and motor control.
• Consideration of medication adjustments where functional impairment affects work capacity.
• Coordination between medication management and return-to-work planning.
• Regular review of medication necessity as the claimant's functional capacity improves.

Independent Medication Review in ACC Contexts

Independent medication reviews by specialist pharmacists provide valuable assessment of medication appropriateness, dependence risk, and functional implications in ACC claims. Medication reviews are particularly valuable in scenarios including:

• Complex polypharmacy requiring assessment and optimization.
• Prolonged opioid or benzodiazepine prescribing.
• Medication-related functional impairment affecting rehabilitation or return to work.
• Disputes regarding medication necessity or appropriateness.
• Transition to long-term medication management in ongoing claims.

Best Practice Medication Governance for ACC Organizations

For organizations managing ACC claims or providing services to ACC claimants, best practice medication governance should include:

• Early assessment: Review medication profile in early claims to identify potential governance concerns or emerging polypharmacy.
• Rehabilitation coordination: Ensure medication management is aligned with rehabilitation planning and return-to-work objectives.
• Specialist engagement: Engage pain specialists, psychiatrists, or other medical specialists for complex medication scenarios.
• Regular review: Establish review protocols for long-term medication use, particularly controlled medications.
• Documentation: Maintain clear records of medication-related communications and clinical reasoning.

Regulatory Developments and Future Trends

New Zealand's medication governance landscape continues to evolve, with increasing focus on opioid stewardship, benzodiazepine deprescribing, and integrated care approaches. The ACC scheme continues to refine guidance on treatment appropriateness and cost-effectiveness, with emphasis on evidence-based interventions supporting rehabilitation and functional recovery.

The growing availability of independent medication review services with specific ACC expertise provides organizations with enhanced capacity to manage medication-related risk and support better claimant outcomes.